CONNECT WITH US
HealthTech

HealthTech

Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M

Endpoints News logo

Published on

Add as a preferred source on Google
Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M

A Parkin­son’s cell ther­a­py biotech and an I&I start­up from for­mer BioN­Tech lead­ers will join the pub­lic mar­kets on Fri­day, ex­tend­ing a siz­zling IPO streak …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug October 29, 2026

For­ma­tion Bio un­veils $600M fund to li­cense and test more drugs October 28, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion

R&D chief Dean Li says Mer­ck out­flanked ri­vals with its sac-TMT can­cer pro­gram

Up­dat­ed: Lil­ly beats rev­enue fore­casts, lift­ing full-year out­look for third straight quar­ter



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.